Results
1 -
10 of
10
(Click
here to explore results)
- Chemical Linkers in Antibody-Drug Conjugates (ADCs), Chapter 11 Trastuzumab Deruxtecan Targeting HER2-expressing Cancers with a DXd-ADC System Consisting of a Novel Protease-sensitive Linker and DNA Topoisomerase I Inhibitor with a Hydroxyl Group. Takashi Nakada, Yuki Abe, Toshinori Agatsuma
, 2022
, Pages 422-450
- Chemical Linkers in Antibody-Drug Conjugates (ADCs), Chapter 3 Linker Design and Impact on ADC Properties. M. Frigerio, N. Camper
, 2022
, Pages 71-135
- Cytotoxic Payloads for Antibody–Drug Conjugates, CHAPTER 8 Topoisomerase Inhibitors as Antibody–Drug Conjugate (ADC) Payloads. Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg
, 2019
, Pages 166-186
- Chemical Linkers in Antibody-Drug Conjugates (ADCs), Chapter 7 ADC Linkers Strategies for the Release of Alcohol-containing Payloads. Jared T. Miller, L. Nathan Tumey
, 2022
, Pages 232-262
- Chemical Linkers in Antibody-Drug Conjugates (ADCs), Chapter 10 Enhancing the Polarity of the Linker-drug in ADCs. Jorin Hoogenboom, Sander S. van Berkel
, 2022
, Pages 377-421
- Nanomedicines: Design, Delivery and Detection, Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101. Ismael Gritli, Edward Garmey, Scott Eliasof, Andres Tellez, Mark E. Davis, Yen Yun
, 2016
, Pages 199-232
- Cytotoxic Payloads for Antibody–Drug Conjugates, Subject Index
, 2019
, Pages 472-480
- Cytotoxic Payloads for Antibody–Drug Conjugates, Contents
, 2019
, Pages P011-P021
- Chemical Linkers in Antibody-Drug Conjugates (ADCs), Chapter 5 Protease-sensitive Linkers. S. Johannes, A. Sommer, H.-G. Lerchen
, 2022
, Pages 173-212
- Cytotoxic Payloads for Antibody–Drug Conjugates, CHAPTER 22 The Future of Antibody–Drug Conjugate (ADC) Payloads. Robert J. Lutz
, 2019
, Pages 461-471